# A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

> **NCT05679258** · PHASE1 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 172 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** HLX15
- **DRUG:** US-sourced DARZALEX®
- **DRUG:** CN-sourced DARZALEX®
- **DRUG:** EU-sourced DARZALEX®

## Key facts

- **NCT ID:** NCT05679258
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-31
- **Primary completion:** 2024-03-16
- **Final completion:** 2024-06-28
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05679258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05679258, "A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05679258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*